<unk>  is an injectable gonadotropin-releasing hormone antagonist (GnRH antagonist). It is primarily used in oncology to reduce the amount of testosterone made in patients with advanced symptomatic prostate cancer for which no other treatment options are available. It belongs to the family of drugs called Gonadotropin-releasing hormone antagonists.
It is marketed by Speciality European Pharma as Plenaxis. Plenaxis has received marketing authorisation in Germany.
Abarelix
Degarelix
Elagolix
Acipimox
Migalastat
Maralixibat
Sonidegib
Miglustat